Betty Yon Son Kim

Betty Yon Son Kim

Auto-generated profile, based on publicly available information

Betty Yon Son Kim

Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, USA

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2008 in Nature Nanotechnology
Verified
Journal Article
Closed access
PDF file
WJWen Jiang
Wen Jiang
BKBetty Y. S. Kim
Betty Y. S. Kim
JRJames T. Rutka
James T. Rutka
WCWarren C. W. Chan
Warren C. W. Chan

16 December 2010 in New England Journal of Medicine
Verified
Journal Article
Closed access
BKBetty Y.S. Kim
Betty Y.S. Kim
JRJames T. Rutka
James T. Rutka
WCWarren C.W. Chan
Warren C.W. Chan
Nanotechnology involves the design of structures measuring 1 to 100 nm in diameter. Nanomaterials are being developed as drug-delivery vehicles, contrast agents, and diagnostic devices, and some are now being studied in clinical trials.

28 August 2019 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
MFMingye Feng
Mingye Feng
WJWen Jiang
Wen Jiang
BKBetty Y. S. Kim
Betty Y. S. Kim
CZCheng Cheng Zhang
Cheng Cheng Zhang
YFYang-Xin Fu
Yang-Xin Fu
IWIrving L. Weissman
Irving L. Weissman

16 December 2019 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
Zhaogang YangZhaogang Yang
Zhaogang Yang
JSJunfeng Shi
Junfeng Shi
JXJing Xie
Jing Xie
YWYifan Wang
Yifan Wang
JSJingyao Sun
Jingyao Sun
LLL. James Lee
L. James Lee

15 January 2018 in Nature Reviews Immunology
Verified
Journal Article
Closed access
PDF file
YHYuhui Huang
Yuhui Huang
BKBetty Y. S. Kim
Betty Y. S. Kim
CCCharles K. Chan
Charles K. Chan
SHStephen M. Hahn
Stephen M. Hahn
IWIrving L. Weissman
Irving L. Weissman
WJWen Jiang
Wen Jiang

9 February 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
NANourhan Abdelfattah
Nourhan Abdelfattah
PKParveen Kumar
Parveen Kumar
CWCaiyi Wang
Caiyi Wang
JLJia-Shiun Leu
Jia-Shiun Leu
WFWilliam F. Flynn
William F. Flynn
KYKyuson Yun
Kyuson Yun
A major rate-limiting step in developing more effective immunotherapies for GBM is our inadequate understanding of the cellular complexity and the molecular heterogeneity of immune infiltrates in gliomas. Here, we report an integrated analysis of 201,986 human glioma, immune, and other stromal cells at the single cell level. In doing so, we discover extensive spatial and molecular heterogeneity in immune infiltrates. We identify molecular signatures for nine distinct myeloid cell subtypes, of which five are independent prognostic indicators of glioma patient survival. Furthermore, we identify S100A4 as a regulator of immune suppressive T and myeloid cells in GBM and demonstrate that deleting S100a4 in non-cancer cells is sufficient to reprogram the immune landscape and significantly improve survival. This study provides insights into spatial, molecular, and functional heterogeneity of glioma and glioma-associated immune cells and demonstrates the utility of this dataset for discovering therapeutic targets for this poorly immunogenic cancer.